title: Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
abstract: BACKGROUND
  The balance between potential aspirin-related risks and benefits is critical in primary prevention.
  
  
  OBJECTIVE
  To evaluate the risk for serious bleeding with regular aspirin use in cardiovascular disease (CVD) primary prevention.
  
  
  METHODS
  PubMed, MEDLINE, Cochrane Central Register of Controlled Trials (2010 through 6 January 2015), and relevant references from other reviews.
  
  
  METHODS
  Randomized, controlled trials; cohort studies; and meta-analyses comparing aspirin with placebo or no treatment to prevent CVD or cancer in adults.
  
  
  METHODS
  One investigator abstracted data, another checked for accuracy, and 2 assessed study quality.
  
  
  RESULTS
  In CVD primary prevention studies, very-low-dose aspirin use (≤100 mg daily or every other day) increased major gastrointestinal (GI) bleeding risk by 58% (odds ratio [OR], 1.58 [95% CI, 1.29 to 1.95]) and hemorrhagic stroke risk by 27% (OR, 1.27 [CI, 0.96 to 1.68]). Projected excess bleeding events with aspirin depend on baseline assumptions. Estimated excess major bleeding events were 1.39 (CI, 0.70 to 2.28) for GI bleeding and 0.32 (CI, -0.05 to 0.82) for hemorrhagic stroke per 1000 person-years of aspirin exposure using baseline bleeding rates from a community-based observational sample. Such events could be greater among older persons, men, and those with CVD risk factors that also increase bleeding risk.
  
  
  CONCLUSIONS
  Power to detect effects on hemorrhagic stroke was limited. Harms other than serious bleeding were not examined.
  
  
  CONCLUSIONS
  Consideration of the safety of primary prevention with aspirin requires an individualized assessment of aspirin's effects on bleeding risks and expected benefits because absolute bleeding risk may vary considerably by patient.
  
  
  BACKGROUND
  Agency for Healthcare Research and Quality.
authors.forename: Evelyn P
authors.initials: EP
authors.lastname: Whitlock
authors.forename: Brittany U
authors.initials: BU
authors.lastname: Burda
authors.forename: Selvi B
authors.initials: SB
authors.lastname: Williams
authors.forename: Janelle M
authors.initials: JM
authors.lastname: Guirguis-Blake
authors.forename: Corinne V
authors.initials: CV
authors.lastname: Evans
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D011322:Primary Prevention; D012307:Risk Factors; D020521:Stroke / Q000139:chemically induced*
chemical_list: D005343:Fibrinolytic Agents; D001241:Aspirin